查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790245

美国药物研发外包市场规模、份额和趋势分析报告：按工作流程、药物、服务、治疗领域、最终用途和细分市场预测，2025-2023 年

U.S. Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Drug, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 203
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

市场规模和趋势

预计 2024 年美国药物研发外包市场价值将达到 24.9 亿美元，2025 年至 2033 年期间的复合年增长率将达到 9.52%。

药物研发外包市场受到以下因素的推动：对候选药物的需求不断增加、慢性病患病率上升、研发支出不断增加、新的官民合作关係关係建立、对专业知识的需求以及復杂标靶治疗的增加。

此外，许多生物製药和製药公司正在转向合约研发外包（CRO）和合约研发生产外包（CDMO），以利用人工智慧、生物资讯学和高效能筛检等先进技术。此外，缺乏强大内部能力的小型虚拟生物技术公司的兴起也进一步推动了外包趋势。

此外，个人化医疗和自适应开发框架的趋势也推动了对外包药物研发服务的需求。全球化、加速新药申请（IND）週期的需求以及新兴治疗领域的涌现，持续推动外包成为关键的成长策略。

此外，个人化医疗的兴起推动了美国药物研发外包领域对适应性小规模製造的需求。随着治疗变得更加有针对性，特别是在肿瘤学、罕见疾病和基因治疗等领域，传统的大规模製造方法正在让位给定製药物开发策略，预计这将在预计的时间内推动市场成长。

委外研发机构(CRO) 和委外研发机构(CDRO) 已成为重要的合作伙伴，利用其模组化基础设施、灵活的工作流程和快速的检测方法开发。外包使生物製药公司能够协调药物设计、患者分层和生物标记主导研究方面的差异，从而提高灵活性、成本效益和速度，将精准疗法推向市场。

此外，人工智慧 (AI) 和机器学习 (ML) 在药物研发领域的日益融合，正在彻底改变化合物识别、优化和检验的流程。 AI 简化了标靶识别、药物相似性评估以及分子交互作用建模，显着缩短了早期研发的时间和成本。此外，ML 演算法能够筛选从体学资料到临床结果的大量资料集，从而发掘创新见解，并最大限度地降低候选化合物筛选的风险。

此外，美国生物製药公司越来越多地将人工智慧解决方案纳入其工作流程，并与专注于人工智慧的委外研发机构(CRO) 合作，以提高生产力，加快临床实验申请 (IND) 的进程，并提高复杂和罕见疾病治疗开发的成功率。例如，2024 年 7 月，Exscientia plc 宣布与亚马逊网路服务 (AWS) 合作，利用该云端供应商的人工智慧和机器学习服务来增强其端到端药物发现和自动化平台。预计这些因素将推动预期週期的成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国药物研发外包市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 临床试验量分析（2024年）
    • 各地区临床试验总数
    • 临床试验总数（依阶段）
    • 临床试验总数（依研究设计）
    • 按主要治疗领域分類的临床试验总数
  • 定价模式分析
  • 科技
  • 市场分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析
    • COVID-19影响分析

第四章：美国药物研发外包市场：依工作流程进行的估算与趋势分析

  • 美国药物研发外包市场（依工作流程）：细分仪表板
  • 美国药物研发外包市场（依工作流程）：波动分析
  • 按工作流程，2021-2033 年
  • 目标识别与筛检
  • 对象检验和功能资讯科学
  • 潜在客户资格审查和候选人优化
  • 临床前开发
  • 其他的

第五章：美国药物研发外包市场：依药物的估计与趋势分析

  • 美国药物研发外包市场（按药物）：细分仪表板
  • 美国药物研发外包市场（按药物）：波动分析
  • 依药物分类，2021-2033 年
  • 小分子
  • 高分子

第六章：美国药物研发外包市场：按服务分類的估算与趋势分析

  • 美国药物研发外包市场（按服务）：细分仪表板
  • 美国药物研发外包市场（按服务）：波动分析
  • 按服务划分，2021-2033 年
  • 化学服务
  • 生物服务

第七章：美国药物研发外包市场（依治疗领域、估价及趋势分析）

  • 美国药物研发外包市场（依治疗领域）：细分仪表板
  • 美国药物研发外包市场（依治疗领域）：波动分析
  • 依治疗领域，2021-2033
  • 呼吸系统
  • 疼痛和麻醉
  • 肿瘤学
  • 眼科
  • 血液学
  • 心血管系统
  • 内分泌
  • 胃肠道
  • 免疫调节
  • 抗感染
  • 中枢神经系统
  • 皮肤科
  • 泌尿生殖系统

第 8 章：美国药物研发外包市场最终用途、估价与趋势分析

  • 美国药物研发外包市场（依最终用途）：细分仪表板
  • 美国药物研发外包市场（依最终用途）：波动分析
  • 依最终用途，2021-2033 年
  • 製药和生物技术公司
  • 学术机构

第九章 竞争态势

  • 市场参与企业分类
  • 2024 年公司市场占有率/估值分析
  • 公司简介
    • Albany Molecular Research Inc.
    • EVOTEC
    • Laboratory Corporation of America Holdings
    • GenScript
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories
    • WuXi AppTec
    • Thermo Fisher Scientific Inc.
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • DiscoverX Corp.
    • QIAGEN
    • Eurofins SE
    • Syngene International Limited
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.
    • Domainex Ltd.

第十章 主要建议

Product Code: GVR-4-68040-281-9

Market Size & Trends:

The U.S. drug discovery outsourcing market size was estimated at USD 2.49 billion in 2024 and is projected to grow at a CAGR of 9.52% from 2025 to 2033. The market for drug discovery outsourcing is driven by growing demand for novel drug candidates, rising incidence of chronic diseases, increasing R&D expenditures, emerging new private-public partnerships, a need for specialized knowledge, and a growing array of complex and targeted therapies.

Besides, most of the biopharmaceutical and pharmaceutical companies are turning to CROs and CDMOs to leverage advanced technologies such as artificial intelligence, bioinformatics, and high-throughput screening. In addition, the rising number of small and virtual biotech companies, which often lack robust internal capabilities, further accelerates the trend toward outsourcing.

Moreover, shifting trends towards personalized medicine and adaptable development frameworks enhances the demand for outsourced discovery services. Globalization, the need for quicker time-to-IND submissions, and the emergence of new therapeutic areas are continuously driving outsourcing as a key strategy for growth.

In addition, the emergence of personalized medicine is driving the need for adaptable, small-batch production within the U.S. drug discovery outsourcing sector. As treatments become increasingly targeted, particularly in areas like oncology, rare diseases, and gene therapy, traditional mass production methods are shifting towards customized drug development strategies, which are expected to drive the market growth over the estimated time period.

Contract research organizations (CROs) and contract development and research organizations (CDROs) utilize a modular infrastructure, flexible workflows, and quick assay development are becoming vital partners. Outsourcing provides biopharma companies with the ability to navigate variability in drug design, patient stratification, and biomarker-driven studies, which in turn enhances their agility, cost-effectiveness, and speed in bringing precision therapies to market.

Furthermore, the growing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the process of identifying, optimizing, and validating compounds. AI streamlines target identification, assesses drug-likeness, and models molecular interactions, leading to significant reductions in early-stage R&D timelines and expenses. Besides, ML algorithms sift through extensive datasets ranging from omics data to clinical outcomes to reveal innovative insights and minimize risks in candidate selection.

In addition, biopharma companies in the U.S. are increasingly incorporating AI-driven solutions into their workflows or collaborating with AI-focused contract research organizations (CROs) to boost productivity, accelerate the path to Investigational New Drug (IND) applications, and enhance success rates in the development of treatments for complex and rare diseases. For instance, in July 2024, Exscientia plc mentioned Amazon Web Services expansion to use the AI & ML services of cloud providers to power the company's platform for end-to-end drug discovery and automation. Such factors are expected to drive the estimated time period.

U.S. Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. drug discovery outsourcing market report based on workflow, drug, service, therapeutics area, end use, and country.

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecules
  • Large Molecules
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemistry Services
  • Biology Services
  • Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Immunomodulation
  • Anti-infective
  • Central Nervous System
  • Dermatology
  • Genitourinary System
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Drug
    • 1.2.3. Service
    • 1.2.4. Therapeutics Area
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Value chain-based analysis
    • 1.7.3. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising R&D cost in biopharmaceutical Industry
      • 3.2.1.2. Increasing access to specialized expertise
      • 3.2.1.3. Growing demand for outsourcing Services in Drug Development
      • 3.2.1.4. Increasing number of partnerships in U.S. Drug Discovery research
      • 3.2.1.5. Technological advancements in drug discovery
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of open-source software packages for drug discovery
      • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
      • 3.2.2.3. Rising Data Security and IP Concerns
      • 3.2.2.4. Regulatory and Compliance Risks
  • 3.3. Clinical Trials Volume Analysis (2024)
    • 3.3.1. Total Number of Clinical Trials, By Region
    • 3.3.2. Total Number of Clinical Trials, By Phase
    • 3.3.3. Total Number of Clinical Trials, By Study Design
    • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
  • 3.4. Pricing Model Analysis
  • 3.5. Technology Landscape
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. U.S. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. U.S. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

  • 5.1. U.S. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
  • 5.2. U.S. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
  • 5.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
  • 6.2. U.S. Drug Discovery Outsourcing Market, By Service: Movement Analysis
  • 6.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Chemistry Services
    • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biology Services
    • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 7.1. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 7.2. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 7.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
  • 7.4. Respiratory system
    • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain and Anesthesia
    • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Ophthalmology
    • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Hematology
    • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Endocrine
    • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Gastrointestinal
    • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.12. Immunomodulation
    • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.13. Anti-infective
    • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.14. Central Nervous System
    • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.15. Dermatology
    • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.16. Genitourinary System
    • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 8.2. U.S. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 8.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 8.4. Pharmaceutical & Biotechnology companies
    • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Academic Institutes
    • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Share/Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Albany Molecular Research Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. EVOTEC
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Laboratory Corporation of America Holdings
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. GenScript
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Pharmaceutical Product Development, LLC
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Charles River Laboratories
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. WuXi AppTec
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Thermo Fisher Scientific Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Dalton Pharma Services
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Oncodesign
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Jubilant Biosys
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. DiscoverX Corp.
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. QIAGEN
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Eurofins SE
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Syngene International Limited
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. Dr. Reddy Laboratories Ltd.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. Pharmaron Beijing Co., Ltd.
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives
    • 9.3.18. TCG Lifesciences Pvt Ltd.
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Financial Performance
      • 9.3.18.3. Service Benchmarking
      • 9.3.18.4. Strategic Initiatives
    • 9.3.19. Domainex Ltd.
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Financial Performance
      • 9.3.19.3. Service Benchmarking
      • 9.3.19.4. Strategic Initiatives

Chapter 10. Key Recommendations

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 6 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 7 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Drug Discovery Outsourcing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Drug Discovery Outsourcing Market: Workflow outlook and key takeaways
  • Fig. 20 U.S. Drug Discovery Outsourcing Market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Drug Discovery Outsourcing Market: Drug outlook and key takeaways
  • Fig. 27 U.S. Drug Discovery Outsourcing Market: Drug movement analysis
  • Fig. 28 Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Drug Discovery Outsourcing Market: Service outlook and key takeaways
  • Fig. 31 U.S. Drug Discovery Outsourcing Market: Service movement analysis
  • Fig. 32 Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Drug Discovery Outsourcing Market: Therapeutics Area outlook and key takeaways
  • Fig. 35 U.S. Drug Discovery Outsourcing Market: Therapeutics Area movement analysis
  • Fig. 36 Respiratory system Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Central NervoU.S. System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. Drug Discovery Outsourcing Market: End Use outlook and key takeaways
  • Fig. 50 U.S. Drug Discovery Outsourcing Market: End Use movement analysis
  • Fig. 51 Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key company categorization
  • Fig. 54 Service heat map analysis
  • Fig. 55 Strategic framework